Tirmed Pharma

TIRmed Pharma is a preclinical-stage biotech developing TIR-01, a topical oligonucleotide cream for atopic dermatitis. The compound aims to break the itch-scratch cycle through a unique immunomodulatory mechanism that temporarily inhibits mast cell degranulation and promotes IL-10 production, offering potential for intermittent dosing and sustained effect. With a seasoned leadership team and strategic partnerships with Bachem and Zelmic, the company is positioning itself to address a significant unmet need in the mild-to-moderate eczema market, particularly for pediatric and young adult populations.

Topical immunomodulatory oligonucleotide platform. Core compound TIR-01 is a single-stranded oligonucleotide formulated in a water-based cream. It acts by temporarily inhibiting mast cell degranulation and dendritic cell activation while stimulating IL-10 production, aiming to recalibrate local skin immunity without systemic immunosuppression.

The atopic dermatitis market is highly competitive, with established topical steroids/calcineurin inhibitors, newer topical JAK inhibitors (e.g., Opzelura), and advanced systemic biologics and pills. TIRmed must differentiate TIR-01 on safety (particularly versus steroids and JAK inhibitors), mechanism, and the potential for sustained effect after intermittent dosing to capture market share in the mild-to-moderate segment.